---
title: "Incyte outlines 2025 milestones with projected $1B in incremental revenue contributions"
date: "2025-02-10 19:52:56"
summary: "Earnings Call Insights: Incyte Corporation (NASDAQ:INCY) Q4 2024 Management View CEO Herve Hoppenot highlighted a strong 2024 performance with total revenues growing 15% year-over-year to $4.2 billion, driven by Jakafi's $2.8 billion net sales and a 50% revenue growth from Opzelura, which reached $508 million. He emphasized the company's continued..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Incyte Corporation (NASDAQ:[INCY](https://seekingalpha.com/symbol/INCY "Incyte Corporation")) Q4 2024

### Management View

* CEO Herve Hoppenot highlighted a strong 2024 performance with total revenues growing 15% year-over-year to $4.2 billion, driven by Jakafi's $2.8 billion net sales and a 50% revenue growth from Opzelura, which reached $508 million. He emphasized the company's continued revenue diversification and robust cash flow, which supported a $2 billion share repurchase and left $2.2 billion in cash with no debt by year-end.
* The FDA approved Niktimvo for chronic GVHD, marking a significant milestone. Commercial launch is underway, targeting approximately 6,000 eligible U.S. patients. The sNDA for ruxolitinib cream in pediatric atopic dermatitis was filed, with a potential approval expected in the second half of 2025.
* Four product launches, including tafasitamab for follicular lymphoma and retifanlimab for squamous cell anal carcinoma, are anticipated in 2025, with projections of $1 billion in incremental revenues by 2029.
* CFO Christiana Stamoulis emphasized strong Q4 results with total revenues of $1.2 billion, up 16% year-over-year, driven by Jakafi and Opzelura. She noted improved operating leverage and margin growth.

### Outlook

* Management provided 2025 guidance for Jakafi net product revenue to range between $2.925 billion and $2.975 billion, driven by demand growth, particularly in polycythemia vera, but partially offset by lower net pricing and increased 340B volumes.
* Opzelura 2025 net product revenue is expected between $630 million and $670 million, supported by demand growth in atopic dermatitis and vitiligo, contributions from Europe, and the potential launch for pediatric atopic dermatitis in the second half of the year.
* Other oncology products are projected to generate $415 million to $455 million in 2025, including contributions from launches of Monjuvi in follicular lymphoma and Zynyz in squamous cell anal carcinoma.

### Financial Results

* Q4 2024 total revenues reached $1.2 billion, with $1 billion in product revenues. Jakafi's Q4 net revenue increased 11% year-over-year to $773 million, while Opzelura's Q4 revenue grew 48% to $162 million. Full-year Opzelura revenues grew to $508 million.
* Total 2024 R&D expenses rose 14% year-over-year due to late-stage development investments, while SG&A expenses increased 7%, reflecting Monjuvi-related costs and European launches.
* Operating leverage improved as total ongoing R&D and SG&A expenses grew at a slower pace than revenues.

### Q&A

* Michael Schmidt, Guggenheim: Asked about pipeline expectations for Opzelura's Phase 3 prurigo nodularis data. CEO Herve Hoppenot noted the bar for success aligns with Phase 2 results, emphasizing its importance for patients with less severe disease.
* Tazeen Ahmad, Bank of America: Inquired about Opzelura's 2025 guidance. CFO Stamoulis explained the growth reflects patient adherence and European contributions, with Q1 dynamics likely to show lower revenue due to typical seasonal factors.
* Jessica Fye, JPMorgan: Questioned the mutant CALR program's potential. COO Pablo Cagnoni highlighted its focus on allele reduction, aiming to address myeloproliferative neoplasms.
* David Lebowitz, Citi: Asked about Medicare Part D redesign impacts on Jakafi. CFO Stamoulis noted reduced out-of-pocket costs, offset by 340B growth.

### Sentiment Analysis

* Analysts expressed cautious optimism regarding the pipeline milestones and financial guidance, with focused questions on pivotal data readouts and commercial launches. Concerns centered around competition in key markets and label-related challenges for JAK inhibitors.
* Management maintained a confident tone during both prepared remarks and Q&A exchanges. CEO Hoppenot emphasized the company's financial strength, while CFO Stamoulis addressed cost dynamics and growth drivers. Phrases like "we expect" and "on track" underscored confidence in 2025 milestones.
* Compared to Q3, the tone remained slightly more optimistic, reflecting confidence in upcoming approvals and launches.

### Quarter-over-Quarter Comparison

* Revenue guidance for Jakafi increased from the Q3 range of $2.74 billion to $2.77 billion to $2.925 billion to $2.975 billion for 2025, indicating stronger expectations driven by polycythemia vera growth.
* Opzelura's performance improved from $139 million in Q3 to $162 million in Q4, reflecting sustained demand in atopic dermatitis and vitiligo.
* Management's tone on pipeline progress was more assertive in Q4, citing concrete milestones and product launch timelines for 2025.

### Risks and Concerns

* Management acknowledged pricing pressures from IRA-imposed caps and increased 340B volumes, which could impact Jakafi's net revenue growth.
* Analysts raised concerns about competition in key markets, especially for povorcitinib and ruxolitinib cream.
* Potential labeling challenges for JAK inhibitors, including safety concerns, could influence commercial uptake.

### Final Takeaway

Incyte delivered robust financial performance in Q4 2024, driven by strong growth in Jakafi and Opzelura revenues. The company outlined significant 2025 milestones, including four product launches and pivotal data readouts, expected to generate $1 billion in incremental revenues by 2029. With a solid financial position and a diversified pipeline, Incyte remains focused on strengthening its market presence while addressing pricing and competitive challenges in key markets.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/INCY/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4405692-incyte-outlines-2025-milestones-with-projected-1b-in-incremental-revenue-contributions)
